JP4786341B2 - 三酸化ヒ素を含む経口組成物の処方およびその使用法 - Google Patents

三酸化ヒ素を含む経口組成物の処方およびその使用法 Download PDF

Info

Publication number
JP4786341B2
JP4786341B2 JP2005500968A JP2005500968A JP4786341B2 JP 4786341 B2 JP4786341 B2 JP 4786341B2 JP 2005500968 A JP2005500968 A JP 2005500968A JP 2005500968 A JP2005500968 A JP 2005500968A JP 4786341 B2 JP4786341 B2 JP 4786341B2
Authority
JP
Japan
Prior art keywords
solution
arsenic trioxide
composition
arsenic
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005500968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503109A5 (enExample
JP2006503109A (ja
Inventor
クマナ・サイラス・ラスタム
クウォン・ヨクラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of JP2006503109A publication Critical patent/JP2006503109A/ja
Publication of JP2006503109A5 publication Critical patent/JP2006503109A5/ja
Application granted granted Critical
Publication of JP4786341B2 publication Critical patent/JP4786341B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2005500968A 2002-10-09 2003-10-08 三酸化ヒ素を含む経口組成物の処方およびその使用法 Expired - Lifetime JP4786341B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41720002P 2002-10-09 2002-10-09
US60/417,200 2002-10-09
US48301403P 2003-06-25 2003-06-25
US60/483,014 2003-06-25
PCT/CN2003/000843 WO2004032822A2 (en) 2002-10-09 2003-10-08 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2006503109A JP2006503109A (ja) 2006-01-26
JP2006503109A5 JP2006503109A5 (enExample) 2006-11-02
JP4786341B2 true JP4786341B2 (ja) 2011-10-05

Family

ID=32096185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005500968A Expired - Lifetime JP4786341B2 (ja) 2002-10-09 2003-10-08 三酸化ヒ素を含む経口組成物の処方およびその使用法

Country Status (6)

Country Link
US (1) US7521071B2 (enExample)
EP (2) EP3106169B1 (enExample)
JP (1) JP4786341B2 (enExample)
CN (1) CN103340899A (enExample)
AU (1) AU2003271510A1 (enExample)
WO (1) WO2004032822A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US8435959B2 (en) 2004-03-29 2013-05-07 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2008046299A1 (en) * 2006-10-11 2008-04-24 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US8795738B2 (en) 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
CN103142648B (zh) * 2011-12-07 2015-04-15 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂
ES2641847T3 (es) 2012-09-20 2017-11-14 Yogesh Narayan BENDALE Proceso para biosintetizar nanotrióxido de arsénico y su uso en el tratamiento de enfermedades que incluyen el cáncer
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
SG11201706150QA (en) 2015-01-29 2017-08-30 Eupharma Pty Ltd Compositions containing arsenic and their use in methods of treatment
US10111836B2 (en) 2015-02-01 2018-10-30 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
IL265986B (en) 2016-12-01 2022-09-01 Eupharma Pty Ltd Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof
CN111184703B (zh) * 2018-11-15 2023-03-28 哈尔滨医大药业股份有限公司 三氧化二砷缓释小丸及其制备方法
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
EP4455672A1 (en) 2023-04-26 2024-10-30 Medsenic Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers
WO2025172482A1 (en) 2024-02-14 2025-08-21 Institut Gustave Roussy Oral composition of arsenic trioxide for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
ES2395515T3 (es) * 1997-11-10 2013-02-13 Memorial Sloan Kettering Cancer Center Trióxido de arsénico para uso en el tratamiento de la leucemia
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
CN1176665C (zh) * 2001-02-15 2004-11-24 暨南大学 治疗恶性淋巴瘤的药物及其配制方法
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Also Published As

Publication number Publication date
EP1562616A4 (en) 2008-12-17
EP3106169B1 (en) 2021-05-19
WO2004032822A3 (en) 2004-12-29
EP3106169A1 (en) 2016-12-21
AU2003271510A1 (en) 2004-05-04
US7521071B2 (en) 2009-04-21
JP2006503109A (ja) 2006-01-26
US20040126434A1 (en) 2004-07-01
EP1562616A2 (en) 2005-08-17
CN103340899A (zh) 2013-10-09
AU2003271510A8 (en) 2004-05-04
EP1562616B1 (en) 2016-06-01
WO2004032822A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
JP4786341B2 (ja) 三酸化ヒ素を含む経口組成物の処方およびその使用法
DK2049109T3 (en) Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
JP7539855B2 (ja) 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
US20220184013A1 (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US20200069677A1 (en) Markers for personalized cancer treatment with lsd1 inhibitors
JP2009510114A (ja) 特定のｒｘｒアゴニストによる癌治療
TWI732084B (zh) 治療atg4相關病症的方法
US20090247495A1 (en) Cucurbitacin b and uses thereof
US20080234244A1 (en) Cucurbitacin b and uses thereof
KR20240137001A (ko) 조혈 면역요법제(hit)로서의 il-12의 용도
TW201642857A (zh) 以組合療法治療肝細胞癌
CN1723029A (zh) 包括三氧化二砷的口服组合物的制剂及其使用方法
WO2008063662A2 (en) Gold (iii) chloride compositions for cancer
WO2008071968A1 (en) Cucurbitacin b and uses thereof
US20240216465A1 (en) Method for treating refractory brain tumor
HK1224955A1 (en) Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060913

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110713

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4786341

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term